Estrella Immunopharma, Inc.(ESLA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ESLA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Estrella Immunopharma, Inc. (ESLA), a Healthcare sector company. ESLA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ESLA by reported 13-F value include ARMISTICE CAPITAL, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. ESLA trades on the Nasdaq exchange and files with the SEC under CIK 1844417. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Estrella Immunopharma, Inc. directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
Operating Income
EPS (Diluted)
Total Assets
-38.8% YoYOp. Cash Flow
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Net Income | — | — | $-7.3M +34.2% | $-11.1M | — | — |
| Operating Income | — | — | $-7.3M +34.2% | $-11.1M | — | — |
| EPS (Diluted) | — | — | $-0.27 +73.3% | $-1.01 | — | — |
| Total Assets | $1.8M -38.8% | $3.0M -33.1% | $4.5M +47.1% | $3.0M -93.3% | $45.4M | — |
| Operating Cash Flow | — | — | $-16.1M -1102.6% | $-1.3M | — | — |
Get alerted when ESLA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Estrella Immunopharma, Inc. including:
Top Institutional Holders of ESLA
ARMISTICE CAPITAL, LLC
$4.1M3,975,220 shVANGUARD CAPITAL MANAGEMENT LLC
$433.5K416,852 shGEODE CAPITAL MANAGEMENT, LLC
$147.0K141,321 shVANGUARD FIDUCIARY TRUST CO
$67.5K64,921 shBlackRock, Inc.
$54.1K52,033 shSTATE STREET CORP
$45.0K43,252 shRENAISSANCE TECHNOLOGIES LLC
$40.7K39,100 shNORTHERN TRUST CORP
$36.3K34,861 shUS BANCORP \DE\
$20.8K20,000 shTower Research Capital LLC (TRC)
$3.4K3,308 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $4.1M | 3,975,220 |
| VANGUARD CAPITAL MANAGEMENT LLC | $433.5K | 416,852 |
| GEODE CAPITAL MANAGEMENT, LLC | $147.0K | 141,321 |
| VANGUARD FIDUCIARY TRUST CO | $67.5K | 64,921 |
| BlackRock, Inc. | $54.1K | 52,033 |
| STATE STREET CORP | $45.0K | 43,252 |
| RENAISSANCE TECHNOLOGIES LLC | $40.7K | 39,100 |
| NORTHERN TRUST CORP | $36.3K | 34,861 |
| US BANCORP \DE\ | $20.8K | 20,000 |
| Tower Research Capital LLC (TRC) | $3.4K | 3,308 |
More Healthcare Companies
View all Healthcare →Put ESLA on your watchlist
Track score changes the day Estrella Immunopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ESLA a good stock to buy?
13F Pro's AI-powered analysis of Estrella Immunopharma, Inc. (ESLA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ESLA are available on the ESLA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ESLA is classified as a small company.
Which hedge funds own ESLA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ESLA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Estrella Immunopharma, Inc.'s investment landscape.